News Redx joins with Jounce to create cancer, fibrosis biotech Merger is announced after Jounce said it will slash staff and seek partners for its programmes.
News Actinium radioligand aces AML trial as filings beckon Survival doubled when Iomab-B was used as a conditioning regimen before a stem cell transplant.
News Daiichi Sankyo wins round in Enhertu patent dispute US PTO has agreed to take another look at whether Seagen's '039 patent is valid.
News Lynparza under siege in first-line prostate cancer New data from Pfizer and J&J encroach on AZ and Merck's territory with the PARP inhibitor.
News Ipsen announces CheckMate 3-yr follow-up aRCC results Ipsen has announced the three-year follow up results from its CheckMate -9ER study
News Gilead buoyed by Trodelvy OK in new breast cancer use The reversal of fortunes for Gilead Sciences' Trodelvy in an advanced form of breast cancer is complete, with an FDA approval unlocking what could be a sizeable new market
News Ipsen' Bylvay fluffs its lines in biliary atresia trial Ipsen's IBAT inhibitor Bylvay has failed a trial in biliary atresia, a rare and serious liver disease that affects babies and has limited treatments.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
